Fig. 4
From: Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015
BI6015 inhibition of gastric cancer (GC) cell growth and WNT signalling. a Cell viability assays were performed in the treatment of BI6015. Six cell lines were selected based on their HNF4α and RhoA protein expression levels, AGS (mid-level RhoA expression), SNU601, SNU668, SNU216, and SNU620 (high-level expression), and MKN1 (low-level expression). The cell lines were treated with 5 and 10μM of the three BI6015 derivatives. b Western blot analysis showing HNF4α and WNT5A protein levels, and the five GC cell lines were treated with the three BI6015 derivatives for 48 h. c Monitoring of WNT signalling activity, using a TCF/LEF-luc reporter luciferase assay, followed by 2µM of the three BI6015 derivatives, for 48 or 96h, in six GC cell lines (SNU1750-, AGS-, MKN45-, NCC24-, NCC59-, NCI-N87-TCF/LEF). Because of the cell viability within the GC cell line panel,17 few cell lines failed to meet the transfection quality to perform TCF/LEF reporter assay. Therefore, we showed different cell lines to explain the study (*p <0.05 and ****p <0.005) (error bar: the standard error of the mean)
